GeoVax Labs (GOVX) Competitors

GeoVax Labs logo
$2.02 +0.32 (+18.48%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.92 -0.10 (-4.70%)
As of 11/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GOVX vs. CDIO, XBIO, CELZ, PMCB, and XTLB

Should you buy GeoVax Labs stock or one of its competitors? GeoVax Labs's main competitors and comparable companies include Cardio Diagnostics (CDIO), Xenetic Biosciences (XBIO), Creative Medical Technology (CELZ), Nuvilex (PMCB), and XTL Biopharmaceuticals (XTLB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GeoVax Labs compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Cardio Diagnostics has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.85, suggesting that its stock price is 285% more volatile than the broader market.

GeoVax Labs has a consensus target price of $3,600.00, suggesting a potential upside of 178,117.82%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Cardio Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, GeoVax Labs had 3 more articles in the media than Cardio Diagnostics. MarketBeat recorded 6 mentions for GeoVax Labs and 3 mentions for Cardio Diagnostics. GeoVax Labs' average media sentiment score of 0.40 beat Cardio Diagnostics' score of -0.01 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardio Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
GeoVax Labs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cardio Diagnostics has higher earnings, but lower revenue than GeoVax Labs. Cardio Diagnostics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$10K529.84-$6.50M-$2.53N/A
GeoVax Labs$2.49M0.41-$21.47M-$11.34N/A

GeoVax Labs has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -89.41% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardio Diagnostics-40,543.75% -89.41% -82.81%
GeoVax Labs N/A -901.14%-392.27%

Summary

GeoVax Labs beats Cardio Diagnostics on 9 of the 16 factors compared between the two stocks.

How does GeoVax Labs compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, GeoVax Labs had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 6 mentions for GeoVax Labs and 3 mentions for Xenetic Biosciences. GeoVax Labs' average media sentiment score of 0.40 beat Xenetic Biosciences' score of -0.04 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company Overall Sentiment
Xenetic Biosciences Neutral
GeoVax Labs Neutral

GeoVax Labs has a consensus price target of $3,600.00, suggesting a potential upside of 178,117.82%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Xenetic Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

GeoVax Labs has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -123.72%. Xenetic Biosciences' return on equity of -53.79% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Xenetic Biosciences-123.72% -53.79% -47.26%
GeoVax Labs N/A -901.14%-392.27%

Xenetic Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.85, indicating that its stock price is 285% more volatile than the broader market.

Xenetic Biosciences has higher revenue and earnings than GeoVax Labs. Xenetic Biosciences is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenetic Biosciences$2.98M1.15-$2.68M-$1.55N/A
GeoVax Labs$2.49M0.41-$21.47M-$11.34N/A

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Xenetic Biosciences beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Creative Medical Technology?

Creative Medical Technology (NASDAQ:CELZ) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

In the previous week, GeoVax Labs had 4 more articles in the media than Creative Medical Technology. MarketBeat recorded 6 mentions for GeoVax Labs and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.65 beat GeoVax Labs' score of 0.40 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creative Medical Technology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
GeoVax Labs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 13.8% of Creative Medical Technology shares are held by insiders. Comparatively, 0.2% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Creative Medical Technology has higher earnings, but lower revenue than GeoVax Labs. Creative Medical Technology is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creative Medical Technology$10K394.76-$5.99M-$1.99N/A
GeoVax Labs$2.49M0.41-$21.47M-$11.34N/A

Creative Medical Technology's return on equity of -101.97% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Creative Medical TechnologyN/A -101.97% -96.74%
GeoVax Labs N/A -901.14%-392.27%

Creative Medical Technology has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.85, meaning that its share price is 285% more volatile than the broader market.

GeoVax Labs has a consensus target price of $3,600.00, suggesting a potential upside of 178,117.82%. Given GeoVax Labs' higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Creative Medical Technology beats GeoVax Labs on 7 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to Nuvilex?

Nuvilex (NASDAQ:PMCB) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Nuvilex has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.85, meaning that its share price is 285% more volatile than the broader market.

Nuvilex's return on equity of -12.99% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
NuvilexN/A -12.99% -8.92%
GeoVax Labs N/A -901.14%-392.27%

GeoVax Labs has a consensus target price of $3,600.00, indicating a potential upside of 178,117.82%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Nuvilex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nuvilex has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuvilexN/AN/A-$19.42M-$43.92N/A
GeoVax Labs$2.49M0.41-$21.47M-$11.34N/A

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, GeoVax Labs had 2 more articles in the media than Nuvilex. MarketBeat recorded 6 mentions for GeoVax Labs and 4 mentions for Nuvilex. GeoVax Labs' average media sentiment score of 0.40 beat Nuvilex's score of -0.05 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvilex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GeoVax Labs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

GeoVax Labs beats Nuvilex on 8 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to XTL Biopharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, GeoVax Labs had 5 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 6 mentions for GeoVax Labs and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat GeoVax Labs' score of 0.40 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
XTL Biopharmaceuticals Very Positive
GeoVax Labs Neutral

GeoVax Labs has a consensus target price of $3,600.00, suggesting a potential upside of 178,117.82%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GeoVax Labs
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

XTL Biopharmaceuticals has higher earnings, but lower revenue than GeoVax Labs. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XTL Biopharmaceuticals$450K8.53-$6.97M-$0.64N/A
GeoVax Labs$2.49M0.41-$21.47M-$11.34N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
XTL BiopharmaceuticalsN/A N/A N/A
GeoVax Labs N/A -901.14%-392.27%

XTL Biopharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.85, meaning that its share price is 285% more volatile than the broader market.

Summary

XTL Biopharmaceuticals and GeoVax Labs tied by winning 7 of the 14 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GOVX vs. The Competition

MetricGeoVax LabsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.04M$4.15B$7.83B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-0.1826.5633.3627.60
Price / Sales0.4116.048.595.73
Price / CashN/A26.3721.9322.50
Price / Book0.044.074.403.70
Net Income-$21.47M-$22.86M$3.52B$392.17M
7 Day Performance-24.51%-6.15%-4.48%-3.37%
1 Month Performance-64.68%-4.92%-3.53%-5.82%
1 Year Performance-99.18%-3.09%0.12%-6.24%

GeoVax Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GOVX
GeoVax Labs
3.0726 of 5 stars
$2.02
+18.5%
$3,600.00
+178,117.8%
-99.3%$1.04M$2.49MN/A19
CDIO
Cardio Diagnostics
0.3053 of 5 stars
$1.82
+10.2%
N/A-47.5%$4.87M$10KN/A17
XBIO
Xenetic Biosciences
0.4075 of 5 stars
$1.85
-1.1%
N/A-42.7%$4.61M$2.98MN/A2
CELZ
Creative Medical Technology
1.9006 of 5 stars
$0.61
-1.6%
N/A-83.5%$4.30M$10KN/A4
PMCB
Nuvilex
0.4804 of 5 stars
$0.41
+13.1%
N/A+607.8%$4.09MN/AN/A2

Related Companies and Tools


This page (NASDAQ:GOVX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners